142 related articles for article (PubMed ID: 36880899)
1. Expanding buprenorphine in U.S. jails: One county's response to addressing the fears of diversion.
Whaley S; Bandara S; Taylor K; Krawczyk N
J Subst Use Addict Treat; 2023 Mar; 146():208944. PubMed ID: 36880899
[TBL] [Abstract][Full Text] [Related]
2. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
3. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail.
Evans EA; Pivovarova E; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
J Subst Abuse Treat; 2022 Jul; 138():108746. PubMed ID: 35249789
[TBL] [Abstract][Full Text] [Related]
4. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
5. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts.
Evans EA; Pivovarova E; Senthilkumar R; Rottapel RE; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
Int J Drug Policy; 2023 Dec; 122():104252. PubMed ID: 37980776
[TBL] [Abstract][Full Text] [Related]
6. Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative.
Krawczyk N; Bandara S; Merritt S; Shah H; Duncan A; McEntee B; Schiff M; Ahmad NJ; Whaley S; Latimore A; Saloner B
Addict Sci Clin Pract; 2022 Jun; 17(1):30. PubMed ID: 35655293
[TBL] [Abstract][Full Text] [Related]
7. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.
Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
Addiction; 2021 Dec; 116(12):3473-3481. PubMed ID: 33999458
[TBL] [Abstract][Full Text] [Related]
8. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
[TBL] [Abstract][Full Text] [Related]
9. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
Dadiomov D; Trotzky-Sirr R; Shooshtari A; Qato DM
Drug Alcohol Depend; 2022 Mar; 232():109291. PubMed ID: 35033953
[TBL] [Abstract][Full Text] [Related]
10. Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting.
Berk J; Del Pozo B; Rich JD; Lee JD
J Addict Med; 2022 Jul-Aug 01; 16(4):396-398. PubMed ID: 34954747
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and treating incarcerated populations for opioid use disorder.
Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
[TBL] [Abstract][Full Text] [Related]
12. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives.
Michener PS; Evans EA; Ferguson WJ; Friedmann PD
Addict Sci Clin Pract; 2024 Feb; 19(1):10. PubMed ID: 38347634
[TBL] [Abstract][Full Text] [Related]
13. Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration.
Monico LB; Gryczynski J; Lee JD; Dusek K; McDonald R; Malone M; Sharma A; Cheng A; DeVeaugh-Geiss A; Chilcoat H
J Subst Abuse Treat; 2021 Apr; 123():108267. PubMed ID: 33612198
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study.
Macmadu A; Adams JW; Bessey SE; Brinkley-Rubinstein L; Martin RA; Clarke JG; Green TC; Rich JD; Marshall BDL
Int J Drug Policy; 2021 May; 91():102841. PubMed ID: 32712165
[TBL] [Abstract][Full Text] [Related]
15. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
[TBL] [Abstract][Full Text] [Related]
16. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.
Evans EA; Wilson D; Friedmann PD
Drug Alcohol Depend; 2022 Feb; 231():109254. PubMed ID: 35063323
[TBL] [Abstract][Full Text] [Related]
17. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Brezel ER; Powell T; Fox AD
Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
[TBL] [Abstract][Full Text] [Related]
18. Assessing provision of MOUD and obstetric care in U.S. jails: A content analysis of policies submitted by 59 jails.
Kao L; Lee C; Parayil T; Kramer C; Sufrin CB
Drug Alcohol Depend; 2023 Jul; 248():109877. PubMed ID: 37244223
[TBL] [Abstract][Full Text] [Related]
19. Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail.
Bailey A; Senthilkumar R; Evans EA
J Addict Med; 2023 Sep-Oct 01; 17(5):568-573. PubMed ID: 37788611
[TBL] [Abstract][Full Text] [Related]
20. The Evolving Medicolegal Precedent for Medications for Opioid Use Disorder in U.S. Jails and Prisons.
Toyoshima T; McNiel DE; Schonfeld A; Binder R
J Am Acad Psychiatry Law; 2021 Dec; 49(4):545-552. PubMed ID: 34341145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
